Skip to main content

Cancer Immunology, Immunotherapy

Ausgabe 2/2024

Inhalt (20 Artikel)

Open Access Meeting Report

Cytokine-induced killer (CIK) cells, successes and challenges: report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy

Amit Sharma, Xiubao Ren, Antonio Rosato, Dario Sangiolo, Zibing Wang, Sarah Tettamanti, Yi Zhang, Eva Rettinger, Kevin Aaron Fenix, Roberta Sommaggio, Elisa Cappuzzello, Ingo G. H. Schmidt-Wolf

Open Access Research

An analysis pipeline for understanding 6-thioguanine effects on a mouse tumour genome

Patricio Yankilevich, Loulieta Nazerai, Shona Caroline Willis, Kjeld Schmiegelow, Daniela De Zio, Morten Nielsen

Open Access Research

Butyricimonas is a key gut microbiome component for predicting postoperative recurrence of esophageal cancer

Koji Otsuka, Junya Isobe, Yoshiyuki Asai, Tomohisa Nakano, Kouya Hattori, Tomotake Ariyoshi, Takeshi Yamashita, Kentaro Motegi, Akira Saito, Masahiro Kohmoto, Masahiro Hosonuma, Atsuo Kuramasu, Yuta Baba, Masakazu Murayama, Yoichiro Narikawa, Hitoshi Toyoda, Eiji Funayama, Kohei Tajima, Midori Shida, Yuya Hirasawa, Toshiaki Tsurui, Hirotsugu Ariizumi, Tomoyuki Ishiguro, Risako Suzuki, Ryotaro Ohkuma, Yutaro Kubota, Takehiko Sambe, Mayumi Tsuji, Satoshi Wada, Yuji Kiuchi, Shinichi Kobayashi, Atsushi Horiike, Satoru Goto, Masahiko Murakami, Yun-Gi Kim, Takuya Tsunoda, Kiyoshi Yoshimura

Open Access Research

Characterization of T cell receptor repertoire in penile cancer

Junying Zhang, Yapeng Wang, Yiqiang Huang, Xintao Tan, Jing Xu, Qian Yan, Jiao Tan, Yao Zhang, Jun Zhang, Qiang Ma, Hailin Zhu, Jin Ye, Zhaojing Zhu, Weihua Lan

Open Access Research

Novel mechanism of drug resistance triggered by tumor-associated macrophages through Heat Shock Factor-1 activation

Alina D. Nikotina, Snezhana A. Vladimirova, Nadezhda E. Kokoreva, Valeria A. Nevdakha, Vladimir F. Lazarev, Liubov S. Kuznetcova, Elena Y. Komarova, Roman V. Suezov, Sergei Efremov, Elizaveta Leonova, Viktor G. Kartsev, Nikolay D. Aksenov, Boris A. Margulis, Irina V. Guzhova

Open Access Research

Personalized neoantigen vaccine enhances the therapeutic efficacy of bevacizumab and anti-PD-1 antibody in advanced non-small cell lung cancer

Xiuhua Lin, Shichuan Tang, Yutong Guo, Ruijing Tang, Zhenli Li, Xinting Pan, Geng Chen, Liman Qiu, Xiuqing Dong, Ling Zhang, Xiaolong Liu, Zhixiong Cai, Baosong Xie

Open Access Research

Unexpected chronic lymphocytic leukemia B cell activation by bisphosphonates

Andrea N. Mazzarello, Elena Gugiatti, Vanessa Cossu, Nadia Bertola, Davide Bagnara, Sonia Carta, Silvia Ravera, Chiara Salvetti, Adalberto Ibatici, Fabio Ghiotto, Monica Colombo, Giovanna Cutrona, Cecilia Marini, Gianmario Sambuceti, Franco Fais, Silvia Bruno

Open Access Research

Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma

J. M. Versluis, E. P. Hoefsmit, H. Shehwana, P. Dimitriadis, J. Sanders, A. Broeks, C. U. Blank

Open Access Research

Presence of Epstein–Barr virus (EBV) antigens detected by sensitive methods has no influence on local immune environment in diffuse large B cell lymphoma

T. Mangiaterra, R. Alonso-Alonso, A. Rabinovich, M. De Dios Soler, L. Galluzzo, M. Soria, S. Colli, E. De Matteo, S. M. Rodriguez Pinilla, P. Chabay

Open Access Research

New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo

Iga Jancewicz, Magdalena Śmiech, Magdalena Winiarska, Radoslaw Zagozdzon, Pawel Wisniewski

Open Access Review

Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions

Xingchen Li, Wenzhi Tian, Zhongxing Jiang, Yongping Song, Xiangyang Leng, Jifeng Yu

Open Access Review

The complex role of IL-10 in malignant ascites: a review

Yue Huang, Kangni Zou, Heng Jiang, Zhengyu Li

Open Access Research

A CAR-T response prediction model for r/r B-NHL patients based on a T cell subset nomogram

Xiaomei Zhang, Rui Sun, Meng Zhang, Yifan Zhao, Xinping Cao, Ruiting Guo, Yi Zhang, Xingzhong Liu, Cuicui Lyu, Mingfeng Zhao

Open Access Research

Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells

Mikel Gurrea-Rubio, Qi Wu, M. Asif Amin, Pei-Suen Tsou, Phillip L. Campbell, Camila I. Amarista, Yuzo Ikari, William D. Brodie, Megan N. Mattichak, Sei Muraoka, Peggy M. Randon, Matthew E. Lind, Jeffrey H. Ruth, Yang Mao-Draayer, Shengli Ding, Xiling Shen, Laura A. Cooney, Feng Lin, David A. Fox

Open Access Research

Unraveling T cell exhaustion in the immune microenvironment of osteosarcoma via single-cell RNA transcriptome

Debin Cheng, Zhao Zhang, Dong Liu, Zhenzhou Mi, Weidong Tao, Jun Fu, Hongbin Fan

Open Access Research

CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1/CTLA-4 bispecific antibody in patients with solid tumors

Jianghua Wang, Xiaoting Li, Guanxi Xiao, Jayesh Desai, Sophia Frentzas, Zhongmin Maxwell Wang, Yu Xia, Baiyong Li

Open Access Research

A comprehensive pan-cancer analysis of prognostic value and potential clinical implications of FTH1 in cancer immunotherapy

Yuejun Luo, Chengming Liu, Yuxin Yao, Xiaoya Tang, Enzhi Yin, Zhiliang Lu, Nan Sun, Jie He

Open Access Review

Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data

Takafumi Yanagisawa, Keiichiro Mori, Akihiro Matsukawa, Tatsushi Kawada, Satoshi Katayama, Kensuke Bekku, Ekaterina Laukhtina, Pawel Rajwa, Fahad Quhal, Benjamin Pradere, Wataru Fukuokaya, Kosuke Iwatani, Masaya Murakami, Karim Bensalah, Viktor Grünwald, Manuela Schmidinger, Shahrokh F. Shariat, Takahiro Kimura

Open Access Research

Enhanced T cell immune activity mediated by Drp1 promotes the efficacy of PD-1 inhibitors in treating lung cancer

Jietao Ma, Jun Song, Xiaofang Yi, Shuling Zhang, Li Sun, Letian Huang, Chengbo Han

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.